Αποτελέσματα Αναζήτησης
5 Ιουν 2023 · Researchers say we appear to be at the start of a new era for Alzheimer’s treatment. Trial results published in January showed that for the first time a drug has been able to slow the cognitive decline characteristic of the disease.
Over half (77%) of the new treatments are touted as potentially disease-modifying, meaning they target known pathological changes in Alzheimer’s disease to slow cognitive decline.
4 Μαΐ 2023 · Promising treatments. FDA approval would make donanemab the third new Alzheimer’s treatment in two years. In January, the agency granted accelerated approval to lecanemab, made by Biogen in...
Genetics & epiGenetics. disease-modifying therapies. These trials, which are the focus of the first section of this report, are evaluating therapies that both treat Alzheimer’s symptoms and address its underlying causes— aiming to stop, slow or even reverse the course of the disease.
2 Οκτ 2023 · Ongoing clinical trials are investigating numerous promising new drugs for AD. The main trends in these trials involve pathophysiology-based, disease-modifying therapies and the recruitment of participants in earlier stages of the disease.
24 Ιουλ 2023 · The Food and Drug Administration (FDA) recently granted full approval to a new Alzheimer’s treatment called lecanemab, which has been shown to moderately slow cognitive and functional decline in early-stage cases of the disease.
5 Μαΐ 2021 · An estimated 50 million people worldwide have dementia, mostly due to Alzheimer’s disease. The inexorable progression of Alzheimer’s disease exerts a huge toll on patients, families, and ...
